Sort   by:  
 Page size 
ProteomicsA Breast Cancer Stem Cell Niche Supported by Juxtacrine Signaling from Monocytes and Macrophages
Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhart F, Donnenberg VS, Bhargava R, Carr SA, Weinberg RA, Nature Cell Biol 2014 in press
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2014-08-04 | MSV000078799 | MassIVE
GenomicsDistinct EMT programs control normal stem cells and cancer stem cells of mammary tissue
Cancer stem cells (CSCs) are proposed to be responsible for metastatic dissemination and clinical relapse in a variety of cancers. Analogies between CSCs and normal tissue stem cells (SC) has led to the notion that CSCs often co-opt the normal SC program of their tissue-of-origin. The cell-biologica...
ORGANISM(S): Mus musculus 
2015-09-02 | E-GEOD-61198 | biostudies-arrayexpress
GenomicsGenome-wide maps of Tbx3 binding sites in mouse ESCs
Induced pluripotent stem (iPS) cells can be obtained through the introduction of defined factors into somatic cells. The combination of Oct4, Sox2 and Klf4 (OSK) constitutes the minimal requirement for generating iPS cells from mouse embryonic fibroblasts (MEFs). Through the genomic analyses of ESC ...
ORGANISM(S): Mus musculus 
2009-12-04 | E-GEOD-19219 | biostudies-arrayexpress
ProteomicsPARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Background: The identification of cancer driver genes from sequencing data has been crucial in deepening our understanding of tumor biology and expanding targeted therapy options. However, apart from the most commonly altered genes, the mechanisms underlying the contribution of other mutations to c...
ORGANISM(S): Homo sapiens (Human) 
2024-04-02 | PXD050844 | Pride
Functional genomics Non-small-cell lung cancer Mechanisms of disease 
ProteomicsDataset14_SUDHL4 SAMHD1 KO 1h 8h Gemcitabine IMPRINTS
SUDHL4 SAMHD1 knockout cells were treated with 24uM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation a...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054912 | JPOST Repository
ProteomicsDataset13_SUDHL4 6h Gemcitabine ATRi IMPRINTS
SUDHL4 cells were treated with vehicle control, 24uM gemcitabine alone, DMSO, 6uM AZD6738 alone, or 24uM Gemcitabine with 6uM AZD6738 for 6h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, ...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054911 | JPOST Repository
ProteomicsDataset12_DLBCL clinical sample 2 5h Gemcitabine ITDR
Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labe...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054910 | JPOST Repository
ProteomicsDataset11_DLBCL clinical sample 1 5h Gemcitabine ITDR
Freshly isolated PBMCs from a R/R DLBCL patient were treated with increasing gemcitabine concentrations (and vehicle control) for 5h, collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labe...
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD054909 | JPOST Repository
ProteomicsDataset08_SUDHL4 1h 8h low dose 2 Gemcitabine IMPRINTS
SUDHL4 cells were treated with 48nM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD055016 | JPOST Repository
ProteomicsDataset07_SUDHL4 1h 8h low dose 1 Gemcitabine IMPRINTS
SUDHL4 cells were treated with 480nM gemcitabine for 1h and 8h (with 8h vehicle control), collected and subjected to CETSA heating, followed by cell lysis, isolation of soluble fraction and sample preparation for MS including digestion, desalting, TMT labeling, offline fractionation and pooling.
ORGANISM(S): Homo Sapiens (human) 
2025-06-12 | PXD055015 | JPOST Repository
Sort   by:  
 Page size